In a TNFα-rich environment, such as in the case of rheumatoid arthritis, we found that anti-TNF therapy prevents the TNFα-induced loss of CD28 on the residual CD28+ CD8+ and CD4+ T cells, but the numbers of CD28null T cells remain the same (194). The gene discussed is TNF; the disease is rheumatoid arthritis.